These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28943551)

  • 41. [The efficacy and safety of edoxaban in non-valvular atrial fibrillation].
    Szegedi A; Csanádi Z
    Orv Hetil; 2018 Mar; 159(12):466-469. PubMed ID: 29552925
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Target-specific oral anticoagulants and the hospitalist.
    Deitelzweig S; Amin A
    Hosp Pract (1995); 2015; 43(1):1-12. PubMed ID: 25559350
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
    Morishima Y; Kamisato C; Honda Y
    Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.
    Furukawa F; Mizawa M; Makino T; Shimizu T
    BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28739563
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
    Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
    Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Peri-Interventional Management of Direct Oral Anticoagulants - Balancing Benefits and Risks].
    Dülgeroglu J; Schmidt D
    Praxis (Bern 1994); 2018 Apr; 107(9-10):485-493. PubMed ID: 29690851
    [No Abstract]   [Full Text] [Related]  

  • 47. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
    Geller BJ; Giugliano RP; Braunwald E; Murphy SA; Hanyok JJ; Jin J; Mercuri M; Antman EM; Ruff CT
    Am Heart J; 2015 Oct; 170(4):669-74. PubMed ID: 26386790
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of factor Xa inhibitors following opening-wedge high tibial osteotomy for venous thromboembolism prophylaxis.
    Kobayashi H; Akamatsu Y; Kumagai K; Kusayama Y; Ishigatsubo R; Mitsuhashi S; Kobayashi A; Aratake M; Saito T
    Knee Surg Sports Traumatol Arthrosc; 2017 Sep; 25(9):2929-2935. PubMed ID: 27000391
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro assessment of edoxaban anticoagulant effect in pediatric plasma.
    Sinegre T; Zlobecki M; Doré E; Pereira B; Grèze V; Lebreton A
    Thromb Res; 2019 Jun; 178():112-118. PubMed ID: 31005667
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
    Fukuda T; Kamisato C; Honda Y; Matsushita T; Kojima T; Furugohri T; Morishima Y; Shibano T
    Thromb Res; 2013 Jun; 131(6):540-6. PubMed ID: 23673387
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thrombosis in an Internal Jugular Vein and an Upper Limb Deep Vein Treated with Edoxaban.
    Toratani M; Hayashi A; Nishiyama N; Nakamura H; Chida R; Komatsu T; Nakahara S; Kobayashi S; Taguchi I
    Intern Med; 2017; 56(9):1053-1055. PubMed ID: 28458311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Direct oral anticoagulant successfully used to treat an adult nephrotic patient complicated with portal vein thrombosis.
    Obata F; Abe H; Murakami T; Ueda S; Inagaki T; Minato M; Ono H; Nishimura K; Shibata E; Tamaki M; Kishi F; Kishi S; Nagai K; Doi T
    CEN Case Rep; 2019 May; 8(2):134-138. PubMed ID: 30721455
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
    Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
    Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
    Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
    Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
    Di Nisio M; Raskob G; Büller HR; Grosso MA; Zhang G; Winters SM; Cohen A
    Thromb Haemost; 2017 Apr; 117(4):784-793. PubMed ID: 28151543
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral anticoagulation with edoxaban. Focus on current phase III clinical development.
    Ahrens I; Bode C
    Hamostaseologie; 2012; 32(3):212-5. PubMed ID: 22786687
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
    Fanikos J; Burnett AE; Mahan CE; Dobesh PP
    Am J Med; 2017 Sep; 130(9):1015-1023. PubMed ID: 28502818
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tranexamic Acid Failed to Reverse the Anticoagulant Effect and Bleeding by an Oral Direct Factor Xa Inhibitor Edoxaban.
    Honda Y; Furugohri T; Morishima Y
    Pharmacology; 2018; 101(1-2):92-95. PubMed ID: 29131074
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Edoxaban approved for embolism prevention.
    Traynor K
    Am J Health Syst Pharm; 2015 Feb; 72(4):258. PubMed ID: 25631826
    [No Abstract]   [Full Text] [Related]  

  • 60. Anticoagulation therapy. Optimal dosages and genotypes for edoxaban therapy.
    Huynh K
    Nat Rev Cardiol; 2015 May; 12(5):256. PubMed ID: 25824520
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.